SavedAdd your journal

Journals / Türk Kadın Sağlığı ve Neonatoloji Dergisi / 2026 / Volume: 6 Issue: 1

Clinical and Demographic Characteristics of Patients Diagnosed with Polycystic Ovary Syndrome: A Cross-Sectional Observational Study

Polikistik Over Sendromu Tanısı Alan Hastaların Klinik ve Demografik Özellikleri: Kesitsel Gözlemsel Çalışma

Özde Beren Tatar(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ETLİK ZÜBEYDE HANIM KADIN HASTALIKLARI SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0009-0005-0524-9942
Osmna Nuri Erginay(UNIVERSITY OF HEALTH SCIENCES, ANKARA ETLİK ZÜBEYDE HANIM HEALTH RESEARCH CENTER FOR GYNECOLOGICAL DISEASES)0009-0007-9804-1941
Yıldız Akdaş Reis(UNIVERSITY OF HEALTH SCIENCES, ANKARA ETLİK ZÜBEYDE HANIM HEALTH RESEARCH CENTER FOR GYNECOLOGICAL DISEASES)0000-0001-9345-6899
Pages
—
Publication Date
2024-03-25
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition to oral contraceptives, which are the treatment of first choice, lifestyle changes are also among the treatments used in patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate the clinical and demographic characteristics of patients diagnosed with polycystic ovary syndrome (PCOS) who were followed up in our hospital.
📊
Key Findings & Data:Material and Methods: We conducted a retrospective, case-controlled observational study of patients treated at the PCOS Clinic of University of Health Sciences Etlik Zubeyde Hanim Women’s Health Training and Research Hospital between November 2023 and January 2024.
💡
Conclusion & Impact:In addition to oral contraceptives, which are the treatment of first choice, lifestyle changes are also among the treatments used in patients.
🔬Design:Research Article
📍Scope:2023 Verileri
⚙️Variables:phenotype · polycystic ovary syndrome · adolescents

Abstract

Objective: The aim of this study was to investigate the clinical and demographic characteristics of patients diagnosed with polycystic ovary syndrome (PCOS) who were followed up in our hospital. Material and Methods: We conducted a retrospective, case-controlled observational study of patients treated at the PCOS Clinic of University of Health Sciences Etlik Zubeyde Hanim Women’s Health Training and Research Hospital between November 2023 and January 2024. The gynecologic history, demographic characteristics, and biochemical parameters of each patient were obtained from the hospital records. Results: The number of patients who presented to our PCOS outpatient clinic and were enrolled in the study was 48, and the mean age of the patients was 23±5.6 years. The mean body mass index was 26.1± 4.9 kg/m2. The most common reason for presentation to the PCOS outpatient clinic was irregular menstruation (83.3%). The most frequently observed phenotypic group was group A (47.9%). The preferred treatment was lifestyle modification (75.0%), the second most common treatment was oral contraceptives (45.8%). Conclusion: PCOS is one of the most common endocrine disorders worldwide and can affect women of all ages. In our study, the most common phenotype in our clinic was found to be group A. In addition to oral contraceptives, which are the treatment of first choice, lifestyle changes are also among the treatments used in patients.

Özet

Amaç: Bu çalışmada polikistik over sendromu (PKOS) tanısı alan ve hastanemizde takipli hastaların klinik ve demografik özelliklerinin değerlendirilmesi planlanmıştır. Gereç ve Yöntem: Kasım 2023- Ocak 2024 tarihleri arasında Ankara Etlik Zübeyde Hanım Araştırma ve Eğitim Hastanesi PKOS Kliniğinde takip edilen hastalar üzerinde retrospektif vaka kontrollü gözlemsel bir çalışma gerçekleştirdik. Her hastanın jinekolojik öyküsü, demografik özellikleri, biyokimyasal parametreleri hastane kayıtlarından elde edilmiştir. Bulgular: PKOS polikliniğimize başvurup, çalışmaya dahil edilen hasta sayısı 48’dir. Hastaların yaş ortalaması 23±5.6 yıldır. Vücut kitle indeksi ortalaması 26,1± 4.9 kg/m2’dir. PKOS polikliniğine en sık başvuru nedeni düzensiz menstrüasyondur (83.3%). En sık gözlemlenen fenotipik grup ise A grubudur (47.9%). Kliniğimize başvuran hastalar en çok yaşam tarzı değişikliği tercih etmiştir (75.0%), ikinci en sık tercih edilen tedavi oral kontraseptif kullanımı (45.8%) olmuştur. Sonuç: PKOS tüm dünyada en sık görülen ve her yaştan kadını etkileyebilen endokrin bozukluklardan biridir. Çalışmamızda kliniğimizde en sık görülen fenotip A grubu olarak bulunmuştur. First line tedavi olan oral kontraseptiflerle birlikte, yaşam tarzı değişşiklikleri de hastalara uygulanan tedavilerimiz arasındadır.

🔖

Cite This Article

Tatar, Ö. B., Erginay, O. N., Reis, Y. A. (2024). Clinical and Demographic Characteristics of Patients Diagnosed with Polycystic Ovary Syndrome: A Cross-Sectional Observational Study. Türk Kadın Sağlığı ve Neonatoloji Dergisi, Volume: 6 Issue: 1. https://doi.org/10.46969/EZH.1445385

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (30)

  1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181. https://doi.org/10.1016/S0002-9378(15)30642-6
  2. Cannarella R, Condorelli RA, Mongioì LM, La Vignera S, Calogero AE. Does a male polycystic ovarian syndrome equivalent exist? J Endocrinol Invest. 2018;41(1):49-57. https://doi.org/10.1007/s40618-017-0728-5
  3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25. https://doi.org/10.1016/j.fertnstert.2003.10.004
  4. World Health Organization. The second decade: improving adolescent health and development (No. WHO/FRH/ADH/98.18 Rev. 1). 2001. Available at: https://apps.who.int/iris/bitstream/ handle/10665/64320/WHO_FRH_?sequence=1
  5. Huffman J. Gynecologic problems that beset the adolescent. Contemporary Obstetrics and Gynecolog. 1976;81-7.
  6. Christensen SB, Black MH, Smith N, et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril. 2013;100(2):470-7. https://doi.org/10.1016/j.fertnstert.2013.04.001
  7. Recabarren SE, Sir-Petermann T, Rios R, et al. Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood. J Clin Endocrinol Metab. 2008;93(9):3318-24. https://doi.org/10.1210/jc.2008-0255
  8. Teede HJ, Misso ML, Costello MF, et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-18.
  9. Güngör ES, Güngör Ş, Zebitay AG. Assessment of semen quality in patients with androgenetic alopecia in an infertility clinic. Dermatologica Sinica. 2016;34(1):10-3. https://doi.org/10.1016/j.dsi.2015.06.003
  10. Witchel SF, Oberfield S, Rosenfield RL, et al. The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr. 2015. https://doi.org/10.1159/000375530
  11. Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr. 2017;88(6):371-95. https://doi.org/10.1159/000479371
  12. Rosenfield RL. Perspectives on the International Recommendations for the Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence. J Pediatr Adolesc Gynecol. 2020;33(5):445-7. https://doi.org/10.1016/j.jpag.2020.06.017
  13. Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee Opinion, Number 789. Obstet Gynecol. 2019;134:e106-14. https://doi.org/10.1097/AOG.0000000000003475
  14. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-92. https://doi.org/10.1210/jc.2013-2350
  15. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-55. https://doi.org/10.1093/humrep/dew218
  16. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45. https://doi.org/10.1210/jc.2006-0178
  17. Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399-405. https://doi.org/10.1210/jc.2010-0334
  18. Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123-9. https://doi.org/10.1093/humrep/der297
  19. de Medeiros SF, de Medeiros MAS, Barbosa BB, Yamamoto MMW, Maciel GAR. Comparison of metabolic and obesity biomarkers between adolescent and adult women with polycystic ovary syndrome. Arch Gynecol Obstet. 2021;303(3):739-749. https://doi.org/10.1007/s00404-020-05867-x
  20. Yuce E, Pabuccu R, Keskin M, Arslanca T, Pabuçcu EG. Polikistik Ovary Sendromlu Ergen ve Yetişkin Hastalar Arasındaki Klinik, Endokrinolojik ve Biyokimyasal Farkların Değerlendirilmesi. TJRMS. 2020;4:15-23. https://doi.org/10.24074/tjrms.2020-80616
  21. Topçu HO, Topçu S, Oskovi A, et al. Comparison of the clinical and laboratory outcomes in adolescent and adults with polycystic ovary syndrome. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi. 2014;11:82-4.
  22. Jain S, Jain M, Shukla RC. Correlation of Clinical, Hormonal, Biochemical and Ultrasound Parameters Between Adult and Adolescent Polycystic Ovarian Syndrome: Adult and Adolescent PCOS. J Obstet Gynaecol India. 2022;72(Suppl 1):274-80. https://doi.org/10.1007/s13224-021-01557-z
  23. Katulski K, Podfigurna A, Czyzyk A, Meczekalski B, Genazzani AD. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine. 2018;61(1):149-57. https://doi.org/10.1007/s12020-018-1609-1
  24. Cimino I, Casoni F, Liu X, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055. https://doi.org/10.1038/ncomms10055
  25. Filho RB, Domingues L, Naves L, Ferraz E, Alves A, Casulari LA. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol. 2007;23(5):267-72. https://doi.org/10.1080/09513590701297708
  26. Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology. 2019;109(1):7-19. https://doi.org/10.1159/000499694
  27. Barber TM, McCarthy MI, Wass JAH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137-45. https://doi.org/10.1111/j.1365-2265.2006.02587.x
  28. Ollila MM, Piltonen T, Puukka K, et al. Weight Gain and Dyslipidemia in Early Adulthood Associate With Polycystic Ovary Syndrome: Prospective Cohort Study. J Clin Endocrinol Metab. 2016;101(2):739-47. https://doi.org/10.1210/jc.2015-3543
  29. Brower MA, Hai Y, Jones MR, et al. Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Hum Reprod. 2019;34(1):127-36. https://doi.org/10.1093/humrep/dey343
  30. Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(6):E1088-96. https://doi.org/10.1210/jc.2013-1295